Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Genital Herpes - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Genital Herpes - Pipeline Review, H1 2016', provides an overview of the Genital Herpes pipeline landscape. The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Genital Herpes - The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects - The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Genital Herpes Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Genital Herpes Overview 9 Therapeutics Development 10 Pipeline Products for Genital Herpes - Overview 10 Pipeline Products for Genital Herpes - Comparative Analysis 11 Genital Herpes - Therapeutics under Development by Companies 12 Genital Herpes - Therapeutics under Investigation by Universities/Institutes 14 Genital Herpes - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Genital Herpes - Products under Development by Companies 17 Genital Herpes - Products under Investigation by Universities/Institutes 18 Genital Herpes - Companies Involved in Therapeutics Development 19 Admedus Ltd 19 AiCuris GmbH & Co. KG 20 Foamix Pharmaceuticals Ltd. 21 Genocea Biosciences, Inc. 22 GenVec, Inc. 23 Immune Design Corp. 24 Immunovaccine, Inc. 25 Mymetics Corporation 26 NanoBio Corporation 27 NanoViricides, Inc. 28 PaxVax, Inc. 29 Profectus BioSciences, Inc. 30 Sanofi Pasteur SA 31 Shulov Innovative Science Ltd. 32 Starpharma Holdings Limited 33 Vaccibody AS 34 Vaxart, Inc. 35 Vical Incorporated 36 Genital Herpes - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 acyclovir - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Aspidasept - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 astodrimer - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 G-103 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 GEN-002 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 GEN-003 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 genital herpes vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 GV-2207 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Herpecide - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 herpes simplex virus [type 1, 2] vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 herpes simplex virus [type 1, 2] vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 herpes simplex virus 2 vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 herpes simplex virus 2 vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 herpes simplex virus 2 vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 herpes simplex virus 2 vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 herpes simplex virus 2 vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 herpes simplex virus 2 vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 herpes simplex virus 2 vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 herpes simplex virus 2 vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 herpes simplex virus 2 vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 HSV-529 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 pritelivir - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 VCLHB-01 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 VCLHM-01 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 ZEP-3 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Genital Herpes - Recent Pipeline Updates 77 Genital Herpes - Dormant Projects 89 Genital Herpes - Discontinued Products 91 Genital Herpes - Product Development Milestones 92 Featured News & Press Releases 92 Feb 03, 2016: Model helps decide drug dose for clinical testing 92 Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 92 Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 93 Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine 94 Aug 17, 2015: NanoViricides Accelerates its Herpes Drug Development Program 95 Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015 96 May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 96 Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences 97 Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes 98 Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection 98 Appendix 100 Methodology 100 Coverage 100 Secondary Research 100 Primary Research 100 Expert Panel Validation 100 Contact Us 100 Disclaimer 101
List of Tables Number of Products under Development for Genital Herpes, H1 2016 10 Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Genital Herpes - Pipeline by Admedus Ltd, H1 2016 19 Genital Herpes - Pipeline by AiCuris GmbH & Co. KG, H1 2016 20 Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 21 Genital Herpes - Pipeline by Genocea Biosciences, Inc., H1 2016 22 Genital Herpes - Pipeline by GenVec, Inc., H1 2016 23 Genital Herpes - Pipeline by Immune Design Corp., H1 2016 24 Genital Herpes - Pipeline by Immunovaccine, Inc., H1 2016 25 Genital Herpes - Pipeline by Mymetics Corporation, H1 2016 26 Genital Herpes - Pipeline by NanoBio Corporation, H1 2016 27 Genital Herpes - Pipeline by NanoViricides, Inc., H1 2016 28 Genital Herpes - Pipeline by PaxVax, Inc., H1 2016 29 Genital Herpes - Pipeline by Profectus BioSciences, Inc., H1 2016 30 Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2016 31 Genital Herpes - Pipeline by Shulov Innovative Science Ltd., H1 2016 32 Genital Herpes - Pipeline by Starpharma Holdings Limited, H1 2016 33 Genital Herpes - Pipeline by Vaccibody AS, H1 2016 34 Genital Herpes - Pipeline by Vaxart, Inc., H1 2016 35 Genital Herpes - Pipeline by Vical Incorporated, H1 2016 36 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Genital Herpes Therapeutics - Recent Pipeline Updates, H1 2016 77 Genital Herpes - Dormant Projects, H1 2016 89 Genital Herpes - Dormant Projects (Contd..1), H1 2016 90 Genital Herpes - Discontinued Products, H1 2016 91
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
